VIZYX.dlm provides many advantages over the traditional manual and silo systems. Here is a short list of some of the most important client-related advantages and benefits available:

Reduces Costs, Expenses, and Complexity

•  Reduces the cost and complexity of achieving and maintaining regulatory compliance compared with available technology and manual systems.
•  Reduces the cost and complexity of managing the Quality system, with fully integrated components such as CAPA; Deviations; Investigations and Change Control to ensure the application of cGMP to products, packaging components, and processes.
• Reduces cost and complexity of Regulatory Systems, by managing product  changes, marketing material updates, SPL filings variations and extensions.
  
• Reduces the cost associated with validation.

Significantly Reduces Regulatory and Financial Risk

•  Eliminates stand-alone, non-integrated systems and manual processes which can create transcription and other errors.
  
• Eliminates multiple data storage across disparate, non-integrated systems thus eliminating another source for potential error.
  
• Unifies data storage to allow for accurate and preemptive management of patient safety, quality, clinical data reducing risk of missing an adverse event information, for example.

Increases Client Efficiency and Productivity

•  Improves information and workflow  transfer across departments, a typical and significant process bottleneck.
  
•  Provides a Knowledge Tool to allow the client to achieve continuous improvement, promote organization-wide standards, facilitate data and information sharing, and provide users with the tools to make better decisions faster.
  
•  Puts a complete view of the data at the finger-tips of all departments. Notifying users, when high risk events occur and guiding them through the compliance process to resolve the events in accordance with cGMPs

Improves Client Management of Drug/Device Lifecycle

• Provides powerful analytical tools that proactively alert management and users to potential risks/threats, particularly in high risk areas such as drug safety, clinical trials and quality systems.
  
• Accelerates new drug development, introduction, and commercialization.
  
• Improves efficient collaboration with partners to accelerate innovation, reduce product and process costs and reduce non-compliance risks.
  
• Supplements drug pipeline through the effective management of partnership and licensing agreements.
  
• Allocates R&D resources more effectively by improving the ability to eliminate poor candidate compounds early.